Multinational pharmaceutical company focused on vaccines, medicines, and consumer health.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
President Trump has signed an executive order directing federal health officials to cut the federal recommended childhood vaccine list, to split the combined MMR vaccine into separate measles, mumps and rubella doses once single‑disease products are available, and to space routine immunisations across separate medical visits. Public health groups and drugmakers have said the changes lack scientific support and will increase missed vaccinations during a major U.S. measles outbreak.
Global markets have steadied as US retail data suggests consumer spending is softer while inflation trends remain in check. Traders are watching for Federal Reserve guidance as major indices hover near records after a week of mixed signals across equities, bonds and currencies.
The Trump administration has urged states to separate the measles, mumps and rubella vaccine into individual shots. Several officials caution that doing so could fuel vaccine hesitancy and leave immunity gaps while some leaders push for more personal choice in immunization policies. New reporting shows the policy debate is unfolding amid mixed messages from health agencies and political leaders.
U.S. stock futures point to gains as Nvidia beats estimates and forecasts strong AI-driven growth; European markets rally on momentum from Nvidia while UK indices turn modestly higher ahead of major earnings and data surprises.
New observational data suggests Shingrix vaccination in older adults is associated with lower cardiovascular risk and reduced dementia incidence over multi-year follow-ups. Studies compare Shingrix to Zostavax and find reductions in heart disease, stroke, and dementia, with stronger signals in men for heart outcomes.
A wave of investments and initiatives is shaping how communities access art and culture. New leadership at Arts Council England, a major Northern art college plan, and local projects in Ulverston and Bradford underscore a push to embed culture in daily life and regional development.